Aurealis Pharma completed a $7.7M capital round from Finnish and Swiss investors
Aurealis Pharma, a Kuopio, Finland and Basel, Switzerland-based private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer, announced that it completed a CHF 7.8M ($7.7M) capital investment round.
The Company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a new legal entity – Aurealis Therapeutics AG. The proceeds of this financing will be used in Aurealis Therapeutics AG to fund the AUP-16 first-in-human Phase 1 clinical study for diabetic foot ulcers (DFU).
Aurelis Pharma, led by CEO Juha Yrjänheikki, was founded in the Finnish city Kuopio in 2010, and today operates from there and from Basel in Switzerland. The company is developing novel three-in-one combination biologic AUP-16 for chronic non-healing wounds and other regenerative diseases. The product is based on Aurealis Pharma
technology where genetically engineered lactic acid bacteria act as millions of small bioreactors in the human tissue and produce multiple human therapeutic proteins into target tissue to effectively and safely re-educate the distorted host immune microenvironment to proper state.